Recommendations for clinical trial development in follicular lymphoma

Kami Maddocks, Paul M. Barr, Bruce D. Cheson, Richard F. Little, Lawrence Baizer, Brad S. Kahl, John P. Leonard, Nathan Fowler, Leo I. Gordon, Brian K. Link, Jonathan W. Friedberg, Stephen Maxted Ansell

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

Original languageEnglish (US)
Article numberdjw255
JournalJournal of the National Cancer Institute
Volume109
Issue number3
DOIs
StatePublished - 2017

Fingerprint

Follicular Lymphoma
Clinical Trials
Therapeutics
Non-Hodgkin's Lymphoma
Biomarkers
Quality of Life
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Maddocks, K., Barr, P. M., Cheson, B. D., Little, R. F., Baizer, L., Kahl, B. S., ... Ansell, S. M. (2017). Recommendations for clinical trial development in follicular lymphoma. Journal of the National Cancer Institute, 109(3), [djw255]. https://doi.org/10.1093/jnci/djw255

Recommendations for clinical trial development in follicular lymphoma. / Maddocks, Kami; Barr, Paul M.; Cheson, Bruce D.; Little, Richard F.; Baizer, Lawrence; Kahl, Brad S.; Leonard, John P.; Fowler, Nathan; Gordon, Leo I.; Link, Brian K.; Friedberg, Jonathan W.; Ansell, Stephen Maxted.

In: Journal of the National Cancer Institute, Vol. 109, No. 3, djw255, 2017.

Research output: Contribution to journalReview article

Maddocks, K, Barr, PM, Cheson, BD, Little, RF, Baizer, L, Kahl, BS, Leonard, JP, Fowler, N, Gordon, LI, Link, BK, Friedberg, JW & Ansell, SM 2017, 'Recommendations for clinical trial development in follicular lymphoma', Journal of the National Cancer Institute, vol. 109, no. 3, djw255. https://doi.org/10.1093/jnci/djw255
Maddocks, Kami ; Barr, Paul M. ; Cheson, Bruce D. ; Little, Richard F. ; Baizer, Lawrence ; Kahl, Brad S. ; Leonard, John P. ; Fowler, Nathan ; Gordon, Leo I. ; Link, Brian K. ; Friedberg, Jonathan W. ; Ansell, Stephen Maxted. / Recommendations for clinical trial development in follicular lymphoma. In: Journal of the National Cancer Institute. 2017 ; Vol. 109, No. 3.
@article{bfc00d2b80054621beeb9893ed92d30d,
title = "Recommendations for clinical trial development in follicular lymphoma",
abstract = "Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20{\%} to 25{\%} of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.",
author = "Kami Maddocks and Barr, {Paul M.} and Cheson, {Bruce D.} and Little, {Richard F.} and Lawrence Baizer and Kahl, {Brad S.} and Leonard, {John P.} and Nathan Fowler and Gordon, {Leo I.} and Link, {Brian K.} and Friedberg, {Jonathan W.} and Ansell, {Stephen Maxted}",
year = "2017",
doi = "10.1093/jnci/djw255",
language = "English (US)",
volume = "109",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Recommendations for clinical trial development in follicular lymphoma

AU - Maddocks, Kami

AU - Barr, Paul M.

AU - Cheson, Bruce D.

AU - Little, Richard F.

AU - Baizer, Lawrence

AU - Kahl, Brad S.

AU - Leonard, John P.

AU - Fowler, Nathan

AU - Gordon, Leo I.

AU - Link, Brian K.

AU - Friedberg, Jonathan W.

AU - Ansell, Stephen Maxted

PY - 2017

Y1 - 2017

N2 - Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

AB - Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non- Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85016062382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016062382&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw255

DO - 10.1093/jnci/djw255

M3 - Review article

C2 - 28040699

AN - SCOPUS:85016062382

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

M1 - djw255

ER -